期刊档案 · Multiple
Hepatoma Research
ISSN 2394-5079 · eISSN 2454-2520 · OAE Publishing Inc.
Hepatoma Research 中科院 医学 4区（2025 年升级版），影响因子 1.8（官网公布），完全开放获取，APC 约 2,600 美元，出版商公布首次决定约 10 天，2025 年发文 29 篇，ESCI、Scopus 收录。
研究范围
研究范围与定位
Hepatoma Research 由 OAE Publishing Inc. 出版，属中科院医学大类（2025 升级版4区）。按 OpenAlex 近年发文统计，该刊主要发表 Liver Disease Diagnosis and Treatment、Hepatocellular Carcinoma Treatment and Prognosis、Hepatitis C virus research 等主题的论文，这 3 个主题约占 56%，主导子领域为 Hepatology。（根据 OpenAlex 主题统计与中科院分区数据生成）
Hepatoma Research focuses on research related to liver cancer, biliary tract cancers, and liver diseases. It covers topics such as their occurrence, development, diagnosis, prevention, and treatment. The journal publishes high-quality basic, translational, clinical, and population-based studies across the continuum of liver oncology and related disciplines. The scope of the journal includes the following areas: • Liver cancer (primary focus)Liver cancer, with a focus on hepatocellular carcinoma, including etiologically and biologically defined disease subtypes associated with hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, metabolic dysfunction, inflammation, immune dysregulation, and viral evolution.Development and validation of diagnostic, prognostic, and predictive biomarkers for liver cancer, including molecular, imaging, and multi-parameter biomarkers relevant to early detection, risk stratification, and assessment of treatment response.Therapeutic strategies and clinical management of liver cancer, including basic and clinical research on animal models, liver transplantation, surgical and interventional therapies, molecular targeted therapy, immunotherapy, combination treatment strategies, treatment-related drugs and complications, and the clinical translation of emerging laboratory discoveries. • Biliary tract cancersMolecular and cellular mechanisms underlying biliary tract cancers, particularly intrahepatic cholangiocarcinoma, with relevance to liver oncology.Diagnostic, prognostic, and predictive biomarkers for biliary tract cancers.Clinical management and therapeutic approaches for biliary tract cancers, including surgical, interventional, systemic, and translational treatment strategies. • Chronic liver diseases associated with liver cancer riskChronic liver diseases that are associated with an increased risk of liver cancer include chronic viral hepatitis, metabolic dysfunction–associated steatotic liver disease, alcohol-related liver disease, liver fibrosis, cirrhosis, and immune-mediated liver diseases.Risk stratification, surveillance strategies, and preventive interventions for liver cancer in patients with high-risk liver diseases.Translational studies linking chronic liver disease biology to hepatocarcinogenesis and early malignant transformation. • Epidemiology and public healthDescriptive epidemiological studies of liver cancer and biliary tract cancers, including an analysis of time trends in incidence, mortality, survi
摘自期刊官网 Aims & Scope
研究方向（LetPub）：Multiple
主编 Guangwen Cao出版商官网
编委会国家分布：中国大陆 40 位（约 40%）；主要国家 中国 40、意大利 19、美国 6、德国 4、中国香港 3（共 99 位编委标注了国家） 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Liver Disease Diagnosis and TreatmentMedicine25.1%
- Hepatocellular Carcinoma Treatment and PrognosisMedicine24.5%
- Hepatitis C virus researchMedicine6.4%
- Cholangiocarcinoma and Gallbladder Cancer StudiesMedicine5.8%
- Hepatitis B Virus StudiesMedicine5.4%
- Liver Disease and TransplantationMedicine3.6%
- Liver physiology and pathologyMedicine3.2%
- Organ Transplantation Techniques and OutcomesMedicine2.8%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 胃肠肝病学GASTROENTEROLOGY & HEPATOLOGY | 4 区 |
| 小类 | 肿瘤学ONCOLOGY | 4 区 |
Top 期刊：否综述期刊：否
《新锐期刊分区表》（ 2026年3月发布）医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 肿瘤学ONCOLOGY | 4 区 |
| 小类 | 胃肠肝病学GASTROENTEROLOGY & HEPATOLOGY | 4 区 |
Top 期刊：否综述期刊：未标注
期刊分区表（ 2023年12月旧的升级版）未收录
该期刊未被此版本分区表收录。
数据库收录
ESCIScopusLetPub
国际期刊预警名单：各版本均未列入LetPub
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子（出版商公布） 2025
- 1.8出版商官网 ·
- CiteScore 2026-06
- 3LetPub ·
- CiteScore（出版商公布）
- 3出版商官网 ·
- SJR 2026-06
- 0.46LetPub ·
- SNIP 2026-06
- 0.35LetPub ·
- h-index
- 26OpenAlex ·
- i10-index
- 121OpenAlex ·
- 两年平均被引
- 1.61OpenAlex ·
- 自引率
- 11.1%LetPub ·
- Gold OA 文章占比
- 100%LetPub ·
发文规模
- 年文章数
- 28LetPub ·
- 年发文量（出版商公布） 2026
- 2,026出版商官网 ·
- 年下载量（出版商公布）
- 1,024,116出版商官网 ·
逐年发文量 OpenAlex 统计 · 累计 638 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 55 | 55 | 16 |
| 2025 | 29 | 29 | 61 |
| 2024 | 53 | 53 | 143 |
| 2023 | 53 | 53 | 147 |
| 2022 | 41 | 41 | 282 |
| 2021 | 78 | 78 | 527 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
- 编辑初审决定
- 10 天出版商官网 ·
- 投稿到首次决定
- 10 天出版商官网 ·
- 评审方式
- 单盲同行评审出版商官网
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
完全开放获取OpenAlex
所有文章开放获取，通常向作者收取文章处理费（APC）。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| 出版商官网 | USD 2,600 | — | — |
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
征稿中的专刊2 个，按截稿日期
出版商官网投稿准备要点8 项，摘自作者指南
- 摘要
- ≤ 250 词
- 关键词
- 3–8 个
- 正文篇幅
- ≤ 3,000 词
- 参考文献格式
- 顺序编码制（按引用顺序编号）
- 稿件模板
- 提供 Word 模板
- 推荐审稿人
- 可选
- 图文摘要
- 必须提供
- 投稿信（Cover letter）
- 必须提供
接收的文章类型13 种
- commentary(1) Figures and TablesFigures and tables should be used judiciously, presented clearly, and designed to strengthen the presentation of evidence and the interpre…未说明篇幅
- editorial(1) Figures and TablesFigures and tables should be used judiciously, presented clearly, and designed to strengthen the presentation of evidence and the interpre…未说明篇幅
- letter to editorA Letter to Editor is usually an open post-publication review of a paper from its readers, often critical of some aspect of a published paper. Controversial pap…未说明篇幅
- meta-analysis(1) Figures and TablesFigures and tables should be used judiciously, presented clearly, and designed to strengthen the presentation of evidence and the interpre…未说明篇幅
- mini review(1) Figures and TablesFigures and tables should be used judiciously, presented clearly, and designed to strengthen the presentation of evidence and the interpre…未说明篇幅
- mini review/reviewA Mini Review/Review article should provide readers with an in-depth understanding of a field by summarizing existing literature, and highlight key gaps and cha…未说明篇幅
- opinion(1) Figures and TablesFigures and tables should be used judiciously, presented clearly, and designed to strengthen the presentation of evidence and the interpre…未说明篇幅
- original article(1) Figures and TablesFigures and tables should be used judiciously, presented clearly, and designed to strengthen the presentation of evidence and the interpre…未说明篇幅
- original research article(1) Figures and TablesFigures and tables should be used judiciously, presented clearly, and designed to strengthen the presentation of evidence and the interpre…未说明篇幅
- perspective(1) Figures and TablesFigures and tables should be used judiciously, presented clearly, and designed to strengthen the presentation of evidence and the interpre…未说明篇幅
- review article(1) Figures and TablesFigures and tables should be used judiciously, presented clearly, and designed to strengthen the presentation of evidence and the interpre…未说明篇幅
- systematic review(1) Figures and TablesFigures and tables should be used judiciously, presented clearly, and designed to strengthen the presentation of evidence and the interpre…未说明篇幅
- technical note(1) Figures and TablesFigures and tables should be used judiciously, presented clearly, and designed to strengthen the presentation of evidence and the interpre…未说明篇幅
官网政策摘录AI 使用、作者资格、利益冲突、数据可用性、出版伦理、许可与版权、开放获取、同行评审、试验注册 / 报告规范
- AI 使用 2.3.3.4 AI and AI-assisted tools Statement
作者应在稿件中披露人工智能及人工智能辅助技术的使用情况；声明这些技术的使用有助于作者、读者、审稿人、编辑和贡献者之间的透明与信任，并便于遵守相关工具或技术的使用条款。如果稿件不涉及此问题，应在本节注明“不适用”。 模型中文摘要
Authors should disclose in their manuscript the use of AI and AI-assisted technologies. Declaring the use of these technologies supports transparency and trust between authors, readers, reviewers, editors and contributors and facilitates compliance with the terms of use of the relevant tool or technology.If the manuscript does not involve this issue, state "Not applicable." in this section.
原文 ↗出版商官网 ·- 作者资格 4. Authorship
OAE期刊的作者署名资格应仅基于对已发表研究的实质性贡献，具体包括以下四项标准：1. 对工作的构思或设计，或数据的获取、分析或解释作出实质性贡献；2. 撰写稿件或对其进行重要的学术内容修改；3. 对拟发表版本进行最终审定；4. 同意对工作的所有方面负责，确保与工作任何部分的准确性或诚信相关的问题得到适当调查。 模型中文摘要
Authorship credit of OAE journals should be solely based on substantial contributions to a published study, as specified in the following four criteria:1. Substantial contributions to the conception or design of the work, or the acquisition, analysis, or interpretation of data for the work;2. Drafting the work or revising it critically for important intellectual content;3. Final approval of the ve…
原文 ↗出版商官网 ·- 利益冲突 2.3.3.6 Conflicts of Interest
作者必须声明任何可能被视为不当影响研究结果表述或解释的潜在利益冲突。如无利益冲突，请在本节注明“所有作者声明不存在利益冲突”。部分作者可能受保密协议约束，在此情况下，我们将要求作者声明“所有作者声明其受保密协议约束，无法披露其在本工作中的利益冲突”，以代替逐项披露。 模型中文摘要
Authors must declare any potential conflicts of interest that may be perceived as inappropriately influencing the representation or interpretation of reported research results. If there are no conflicts of interest, please state "All authors declared that there are no conflicts of interest." in this section. Some authors may be bound by confidentiality agreements. In such cases, in place of itemiz…
原文 ↗出版商官网 ·- 数据可用性 2.3.3.3 Availability of Data and Materials
为保持研究记录的完整性、透明性和可重复性，作者应在稿件中包含本节，详细说明支持其发现的数据所在位置。数据可存入数据存储库或作为期刊补充信息发表。无法共享数据的作者应声明数据不予共享并说明原因。如果稿件不涉及此类问题，请注明“不适用”。 模型中文摘要
In order to maintain the integrity, transparency and reproducibility of research records, authors should include this section in their manuscripts, detailing where the data supporting their findings can be found. Data can be deposited into data repositories or published as supplementary information in the journal. Authors who cannot share their data should state that the data will not be shared an…
原文 ↗出版商官网 ·- 出版伦理 2.3.3.7 Ethical Approval and Consent to Participate
Member of COPE, adheres to Code of Conduct and Best Practice Guidelines 模型摘要
Research involving human subjects, human material or human data must be performed in accordance with the Declaration of Helsinki and approved by an appropriate ethics committee. An informed consent to participate in the study should also be obtained from participants, or their parents or legal guardians for children under 16. A statement detailing the name of the ethics committee (including the re…
原文 ↗出版商官网 ·- 许可与版权 1.2 Open Access and Copyright
该期刊自创刊起采用金色开放获取出版模式，自2017年10月起依据“署名4.0国际许可协议”（CC BY 4.0）发布内容，此前采用“署名-非商业性使用-相同方式共享3.0未本地化版本”许可协议。版权由作者保留。请确保您充分了解这些政策。 模型中文摘要
The journal adopts Gold Open Access publishing model since its establishment and has been distributing contents under Attribution 4.0 International License since October 2017, whereas Attribution-NonCommercial-ShareAlike 3.0 Unported had been adopted by then. Copyright is retained by authors. Please make sure that you are well aware of these policies.
原文 ↗出版商官网 ·- 开放获取 1.2 Open Access and Copyright
该期刊自创刊起采用金色开放获取出版模式，自2017年10月起依据“署名4.0国际许可协议”（CC BY 4.0）发布内容，此前采用“署名-非商业性使用-相同方式共享3.0未本地化版本”许可协议。版权由作者保留。请确保您充分了解这些政策。 模型中文摘要
The journal adopts Gold Open Access publishing model since its establishment and has been distributing contents under Attribution 4.0 International License since October 2017, whereas Attribution-NonCommercial-ShareAlike 3.0 Unported had been adopted by then. Copyright is retained by authors. Please make sure that you are well aware of these policies.
原文 ↗出版商官网 ·- 同行评审 7.3 AI Use in Peer Review
Confidentiality requirements: Reviewers must not upload manuscripts/materials to AI platforms, as this: 1. Violates OAE’s confidentiality policies2. Risks intellectual property infringement3. May compromise personal data in identifiable content Review integrity standards: Peer review must remain human-driven – AI tools cannot replace critical scholarly judgment.Reviewers must not use AI for manusc…
原文 ↗出版商官网 ·- 试验注册 / 报告规范 3.1.5 Trial Registration
OAE requires all authors to register all relevant clinical trials that are reported in manuscripts submitted. OAE follows the World Health Organization (WHO)'s definition of clinical trials: "A clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. Interventions i…
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- OAE Publishing Inc.
- ISSN
- 2394-5079
- 电子版 ISSN
- 2454-2520
- 官方链接
- 期刊主页 ↗OpenAlex
- 专刊 / 特刊征稿 ↗出版商官网
常见问题
关于 Hepatoma Research 的常见问题
Hepatoma Research 是中科院几区期刊？
2025 年升级版分区表中，Hepatoma Research 为医学 4区，小类 胃肠肝病学 / 肿瘤学 4 区。2026 年新锐版分区表中为医学 4区。不同版本与大小类分区不能混用。
Hepatoma Research 的影响因子是多少？
期刊官网公布的影响因子为 1.8（2025 年度），属期刊自述数据，LetPub 暂无该刊的影响因子记录，CiteScore 为 3，h-index 为 26。
Hepatoma Research 的审稿周期多长？
出版商公布的投稿到首次决定时间约为 10 天（首次决定含直接拒稿）。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
Hepatoma Research 的投稿格式要求是什么？
据期刊作者指南：摘要：≤ 250 词；关键词：3–8 个；正文篇幅：≤ 3,000 词；参考文献格式：顺序编码制（按引用顺序编号）；稿件模板：提供 Word 模板；推荐审稿人：可选；图文摘要：必须提供；投稿信：必须提供。以上由模型从作者指南提取并逐项与原文核对，投稿前请以官网最新版本为准。
Hepatoma Research 的编委会里有中国学者吗？
期刊官网编委会页面上标注了国家的 99 位编委中，中国大陆 40 位（约 40%）；人数最多的国家是 中国（40 位）、意大利（19 位）、美国（6 位）。统计按编委会页面列出的机构国家计，仅供参考。
Hepatoma Research 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，Hepatoma Research 被 ESCI、Scopus 收录。
Hepatoma Research 是开放获取期刊吗？版面费多少？
Hepatoma Research 为完全开放获取。APC 约 2,600 美元。
来源与更新
本页事实来自 LetPub、出版商官网、OpenAlex；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-25 归档）。最近更新：。